Built on the proprietary UNK-Oral platform, we overcome the oral delivery challenge of peptide drugs, achieving effective intestinal absorption of active peptides and breaking through the injection-only limitation of traditional peptide drugs to develop convenient oral peptide formulations.
Advantages
Revolutionary Delivery
Replacing injection with oral administration greatly improves patient compliance and supports long-term chronic disease management.
Enhanced GI Stability
The UNK-Oral platform improves gastrointestinal stability of peptide drugs, preserving biological activity and increasing absorption.
Principle
The proprietary UNK-Oral oral peptide delivery technology uses a dedicated gastrointestinal molecular protection system to resist degradation by gastric acid and digestive proteases, maintaining peptide integrity and improving transmembrane transport.
Applications
This technology has been successfully applied to the development of long-acting GLP-1 hypoglycemic drugs, converting traditional injectables into oral dosage forms for type 2 diabetes and obesity while retaining the long half-life advantage.
